Publications
213
Citations
6,768
Est. group size
~7
Recurring co-author estimate
Active years
25
Publishing since 2002
Monica Venere studies brain tumors, particularly glioblastoma and other gliomas, focusing on how cancer cells resist treatment and how genetic and epigenetic changes (modifications affecting gene activity without altering DNA sequence) drive tumor growth. Her work investigates potential drug targets, such as proteins involved in DNA repair and chromatin (the packaging of DNA in cells), aiming to identify treatments that make brain tumors more sensitive to radiation and chemotherapy. This research is largely preclinical, using laboratory and animal models to test new therapeutic strategies before they might reach clinical trials.
Publication counts fluctuated over the past decade with a notable spike in 2023 (largely due to a single multi-part dataset publication), followed by a return to lower, more typical annual output in subsequent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Cell death pathways and chemotherapy in brain tumors
Elsevier eBooks · 2026
- Identification of Triapine as a Novel Radiosensitizer in Glioblastoma
International Journal of Radiation Oncology*Biology*Physics · 2024
- EPEN-04. OVERWHELMING ZFTA-RELA NUCLEAR LOCALIZATION AS A THERAPEUTIC STRATEGY AGAINST EPENDYMOMA
Neuro-Oncology · 2024
- Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey
Neuro-Oncology Practice · 2024
- Data from Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
2023
- Data from Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
2023
- Data from Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
2023
- Data from Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
2023
- Abstract 2407: Targeting ribonucleotide reductase subunit 2 (RRM2) to radio-sensitize glioblastoma
Cancer Research · 2023
- Supplementary Methods, Figures 1 - 11 from Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
2023
- Supplementary Methods, Figures 1 - 11 from Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells
2023
- Supplemental Materials & Methods from Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
2023
- Supplementary Figure S3 from Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
2023
- Supplementary Figure S4 from Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
2023
- CSC Conference program from Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance
2023
- Neuro-Oncology×20
- Science Translational Medicine×8
- Elsevier eBooks×4
- Electrophoresis×3
- Cancer Letters×3
- Aline Paixão Becker
Medicine · The Ohio State University
- Arnab Chakravarti
Medicine · The Ohio State University
- Pedro C. Silberman
Medicine · The Ohio State University
- Sara Khan
Medicine · The Ohio State University
- Pierre Giglio
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile